BACKGROUND: Crohn's disease (CD) of the pouch can develop in patients with ileal pouch-anal anastomosis (IPAA). Scant data are available on the treatment of this disease entity. AIM: To evaluate efficacy and safety of adalimumab in treating CD of the ileal pouch. METHODS: From June 2007 to June 2008, 17 IPAA patients with inflammatory (n = 10), fibrostenotic (n = 2) or fistulizing (n = 5) CD of the pouch treated with adalimumab were evaluated. Inclusion criteria were CD of the pouch who failed medical therapy and were otherwise qualified for permanent pouch diversion or excision. All qualified patients received the standard dosing regimen of subcutaneous injection adalimumab (160 mg at week 0, 80 mg at week 1, and 40 mg every other week thereafter). Complete clinical response was defined as resolution of symptoms. Partial clinical response was defined as improvement in symptoms. Endoscopic inflammation before and after therapy was recorded, using the Pouchitis Disease Activity Index (PDAI) endoscopy subscores. RESULTS: The median age was 36 years with 12 patients (70.6%) being male. At 4 weeks, seven patients (41.2%) had a complete symptom response and 6 (35.3%) had a partial response. There was also a significant improvement in the PDAI endoscopy subscores at week 4 (P < 0.05). At the last follow-up (median of 8 weeks), eight patients (47.1%) had a complete symptom response and 4 (23.5%) had a partial response. Four patients (23.6%) developed adverse effects. Three patients (17.7%) eventually had pouch failure after failing to respond to adalimumab therapy. CONCLUSION: Adalimumab appeared to be well-tolerated and efficacious in treating CD of the pouch in this open-labelled induction study.
BACKGROUND:Crohn's disease (CD) of the pouch can develop in patients with ileal pouch-anal anastomosis (IPAA). Scant data are available on the treatment of this disease entity. AIM: To evaluate efficacy and safety of adalimumab in treating CD of the ileal pouch. METHODS: From June 2007 to June 2008, 17 IPAA patients with inflammatory (n = 10), fibrostenotic (n = 2) or fistulizing (n = 5) CD of the pouch treated with adalimumab were evaluated. Inclusion criteria were CD of the pouch who failed medical therapy and were otherwise qualified for permanent pouch diversion or excision. All qualified patients received the standard dosing regimen of subcutaneous injection adalimumab (160 mg at week 0, 80 mg at week 1, and 40 mg every other week thereafter). Complete clinical response was defined as resolution of symptoms. Partial clinical response was defined as improvement in symptoms. Endoscopic inflammation before and after therapy was recorded, using the Pouchitis Disease Activity Index (PDAI) endoscopy subscores. RESULTS: The median age was 36 years with 12 patients (70.6%) being male. At 4 weeks, seven patients (41.2%) had a complete symptom response and 6 (35.3%) had a partial response. There was also a significant improvement in the PDAI endoscopy subscores at week 4 (P < 0.05). At the last follow-up (median of 8 weeks), eight patients (47.1%) had a complete symptom response and 4 (23.5%) had a partial response. Four patients (23.6%) developed adverse effects. Three patients (17.7%) eventually had pouch failure after failing to respond to adalimumab therapy. CONCLUSION:Adalimumab appeared to be well-tolerated and efficacious in treating CD of the pouch in this open-labelled induction study.
Authors: Zhao-xiu Liu; Tom Deroche; Feza H Remzi; Jefferey P Hammel; Victor W Fazio; Run-zhou Ni; John R Goldblum; Bo Shen Journal: Surg Endosc Date: 2011-06-10 Impact factor: 4.584
Authors: Martin Gregory; Kimberly N Weaver; Patrick Hoversten; Stephen Bradley Hicks; Devin Patel; Matthew A Ciorba; Alexandra M Gutierrez; Poonam Beniwal-Patel; Sowmya Palam; Gaurav Syal; Hans H Herfarth; George Christophi; Laura Raffals; Edward L Barnes; Parakkal Deepak Journal: Inflamm Bowel Dis Date: 2019-08-20 Impact factor: 5.325